Delayed peak antibody titers after the second dose of SARS-CoV-2 vaccine in solid organ transplant recipients: Prospective cohort study
Kohei Unagami,Mikiko Yoshikawa,Hiroto Egawa,Satoko Ohfuji,Yoichiro Natori,Rikako Oki,Tomomi Mori,Hidetoshi Hattori,Ayumi Ishiwatari,Taichi Kanzawa,Tomokazu Shimizu,Kazuya Omoto,Masashi Inui,Yuuki Masano,Takashi Ito,Daisuke Nakajima,Tetsuya Babazono,Toshio Takagi,Shinichi Nunoda,Yoshito Tomimaru,Ryoichi Imamura,Shigeru Miyagawa,Koichi Toda,Etsuro Hatano,Hiroshi Date,Miyaji Kyakuno,Shiro Takahara,Kenji Yuzawa,Naoki Tanimine,Hideki Ohdan,Hideki Ishida,Yoshio Hirota,Japan Solid Organ Transplantation COVID-19 Countermeasure Group
DOI: https://doi.org/10.1016/j.vaccine.2024.126221
IF: 4.169
2024-08-23
Vaccine
Abstract:Poor post-vaccination production of antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a concern among solid organ transplant (SOT) recipients. Furthermore, the timing and kinetics of antibody titers after the second vaccine dose are unknown. We conducted a multicenter prospective observational study that included 614 SOT recipients: 460 kidney, 53 heart, 50 liver, 20 lung, and 31 simultaneous pancreas-kidney (SPK). The participants received two doses of the mRNA vaccine (Pfizer BNT162b2 or Moderna mRNA-1273), as indicated. Serum samples were collected before the first and second vaccinations and at 1, 3, and 6 months after the second vaccine dose, which were then assessed for SARS-CoV-2 antibodies. The overall seropositivity rate was 43% at 1 month after administration of the second vaccine dose; it gradually increased to 68% at 3 months after second dose administration and to 70% at 6 months. In addition, recipient of kidney, lung or SPK transplants had lower antibody titers at the 3- and 6-month time points than did the other recipients. SOT recipients acquired SARS-CoV-2 S-IgG antibodies slowly, and the peak titer differed significantly from that of the general population.